Author:
Licata Maria Angela Vittoria,Porro Lucia Maria,Sgalla Giacomo,Richeldi Luca
Abstract
A 59-year-old patient without a history of pulmonary disease presented with episodes of hemoptysis and acute respiratory failure after receiving fulvestrant and palbociclib for metastatic breast cancer. The High-Resolution chest CT demonstrated diffuse ground glass opacities, as well as diffuse smooth thickening of the interlobular septa and peribronchovascular interstitium, which are consistent with Drug-Induced Interstitial Lung Disease (DIILD). A few days of high-dose steroid therapy improved the patient's gas exchange from PaO2/FiO2 of 75 to 200. After hospital discharge, the oncologist resumed fulvestrant therapy, with no additional adverse events occurring during the subsequent follow-up.
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference6 articles.
1. (1) Spagnolo P, Bonniaud P, Rossi G, et al. Drug-induced interstitial lung disease. European Respiratory Journal 2022;60:2102776.
2. (2) Skeoch S, Weatherley N, Swift A, et al. Drug-Induced Interstitial Lung Disease: a Systematic Review J Clin Med 2018;7:356.
3. (3) Levy O, Ptashkin E, Shechtman Y, et al. Fatal Palbocyclib-Related Interstitial Pneumonitis. Archives of Clinical and Medical Case Reports 2019;3:162-6.
4. (4) Zhang Y, Ma Z, Sun X, et al. Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials. Breast 2022;62:162-9.
5. (5) Raschi E, Fusaroli M, Ardizzoni A, et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat 2021;186:219-27.